Validation of the point-EXACCT method in non-small cell lung carcinomas

Clinical Chemistry

Volumn 44, Issue 7, 1998, Pages 1404-1409

  Somers, Veerle A M C ^a   Leimbach, Darcy A ^b   Theunissen, Paul H M H ^c   Murtagh Jr , James J ^b   Holloway, Brian ^d   Ambergen, Anton W ^a   Thunnissen, Frederik B J M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b EMORY UNIVERSITY   (United States)

^c De Wever Hospital ^*  (Netherlands)

^d NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LABORATORY TEST; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; POINT MUTATION;

EID: 0031831454     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.7.1404     Document Type: Article

References (50)

1. Bos JL. The ras gene family and human carcinogenesis. Mutat Res 1988;195:255-71.
2. Barbacid M. Ras genes. Annu Rev Biochem 1987;56:779-827.
3. Rodenhuis S, Slebos RJ. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 1992;52(Suppl 9):2665s-9s.
4. Kern JA, Slebos RJC, Top B, Rodenhuis S, Lager D, Robinson RA, et al. c-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 1994;93:516-20.
5. Mitsudomi T, Viallet J, Mulshine JL, Linnoila RI, Minna JD, Gazdar AF. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 1991;6:1353-62.
6. Rodriguez-Viciana P, Warne PH, Khwaja A, Matte BM, Pappin D, Das P, et al. Role of phospoinoside 3-OH kinase in cell transformation and control of the actin cytoskeleton by ras. Cell 1997: 89:457-67.
7. Keohavong P, DeMichele MAA, Melacrinos AC, Landreneau RJ, Weyant RJ, Siegfried JM. Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin Cancer Res 1996;2: 411-8.
8. Rodenhuis S, Slebos R, Boot A, Evers S. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res 1988;48:5738-41.
9. Suzuki Y, Orita M. Shiraishi M, Hayashi K, Sekiya T. Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 1990;5:1037-43.
10. Sugio K, Ishida T, Yokoyama H, Inoue T, Sugimachi K, Sasazuki T. Ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 1992;52:2903-6.
11. Kobayashi T, Tsua H, Noguchi M, Hirohashi S, Shimosato Y, Goya T, et al. Association of point mutation in c-Ki-ras oncogene in lung adenocarcinoma with particular reference to cytologic subtypes. Cancer 1990;66:289-94.
12. Mills NE, Fishman CL, Rom WM, Dubin N, Jacobson DR. Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res 1995;55:1444-7.
13. Yakubovskaya MS, Spiegelman V, Luo FC, Malaev S, Salnev A, Zborovskaya I, et al. High frequency of K-ras mutations in normal appearing lung tissues and sputum of patients with lung cancer. Int J Cancer 1995;63:810-4.
14. Vachtenheim J, Horáková I, Novotná H, Opálka P, Roubková H. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung. Clin Cancer Res 1995;1:359-65.
15. Li Z-H, Zheng J, Weiss LM, Shibata D. c-K-ras, p53 mutations occur very early in adenocarcinoma of the lung. Am J Pathol 1994;144:303-9.
16. Yano T, Yuasa M, Murakami A, Ichikawa T, Hagiwara K. The detection of chemically initiated cells having the mutation of K-ras gene at an early stage of lung carcinogenesis in mice. Anal Biochem 1997;244:187-9.
17. Leone-Kabler S, Wessner LL, McEntree MF, D'Agostino RBD, Miller MS. Ki-ras mutations are an early event and correlate with tumor stage in transplacentally-induced murine lung tumors. Carcinogenesis 1997;18:1163-8.
18. Mao L, Lee JS, Kurie JM, Fan YH, Lippman SM, Lee JJ, et al. Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 1997;89:857-62.
19. Wistuba II, Lam S, Behrens C, Virmani AK, Fong KM, LeRiche J, et al. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst 1997;89:1366-73.
20. Slebos RJ, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJ, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990;323:561-5.
21. Westra W, Slebos R, Offerhaus G, Goodman S, Evers S, Kensler T, et al. K-ras oncogene activation in lung adenocarcinomas from former smokers. Cancer 1993;72:432-8.
22. Husgafvel-Pursiainen K, Hackman P, Ridanpaa M, Anttila S, Karjalainen A, Partanen T, et al. K-ras mutations in human adenocarcinoma of the lung: association with smoking and occupational exposure to asbestos, Int J Cancer 1993;53:250-6.
23. Vaino H, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Hackman P, Partanen T. Interaction between smoking and asbestos in human lung adenocarcinoma: role of K-ras mutations. Environ Health Perspect 1993;101(Suppl 3):189-92.
24. Rosell R, Li S, Skacel Z, Mate JL, Maestre J, Canela M, et al. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene 1993;8:2407-12.
25. Wagner SN, Müller R, Boehm J, Pütz B, Wünsch PH, Höfler H. Neuroendocrine neoplasms of the lung are not associated with point mutations at codon 12 of the Ki-ras gene. Virchows Arch B Cell Pathol 1993;63:325-9.
26. Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 1989;17:2503-16.
27. Chen Z-Y, Zarbl H. A nonradioactive, allele-specific polymerase chain reaction for reproducible detection of rare mutations in large amounts of genomic DNA: application to human K-ras. Anal Biochem 1997;244:191-4.
28. Cha R, Zarbl H, Keohavong P, Thilly W. Mismatch Amplification Mutation Assay (MAMA): application to the c-H-ras gene. PCR Methods Appl 1992;2:14-20.
29. Nickerson DA, Kaiser R, Lappin S, Stewart J, Hood L. Automated DNA diagnostics using an ELISA-based oligonucleotide ligation assay. Proc Natl Acad Sci U S A 1990;87:8923-7.
30. Lehman TA, Scott F, Seddon M, Kelly K, Dempsey EC, Wilson VL, et al. Detection of K-ras oncogene mutations by polymerase chain reaction-based ligase chain reaction. Anal Biochem 1996;239:153-9.
31. Chen J, Viola MV. A method to detect ras point mutations in small subpopulations of cells. Anal Biochem 1991;195:51-6.
32. Kahn SM, Jiang W, Culbertson TA, Weinstein IB, Williams GM, Tomita N, et al. Rapid and sensitive nonradioactive detection of mutant K-ras genes via 'enriched' PCR amplification. Oncogene 1991;6:1079-83.
33. Jacobson DR, Mills NE. A highly sensitive assay for mutant ras genes and its application to the study of presentation and relapse genotypes in acute leukemia. Oncogene 1994;9:553-63.
34. Mao L, Hruban RH, Boyle JO, Tockman M, Sidransky D. Detection of oncogens mutations in sputum precedes diagnosis of lung cancer. Cancer Res 1994;54:1634-7.
35. Somers VAMC, Moerkerk PTM, Murtagh JJ Jr, Thunnissen FBJM. A rapid, reliable method for detection of known point mutations: Point-EXACCT. Nucleic Acids Res 1994;22:4840-1.
36. Somers VAMC, Leimbach DA, Murtagh JJ, Thunnissen FBJM. Exonuclease enhances hybridization efficiency: improved direct cycle sequencing and point mutation detection. Biochim Biophys Acta 1998;1379:42-52.
37. Carpenter KM, Durrant LG, Morgan K. Bennett D, Hardcastle JD, Kalsheker NA. Greater frequency of K-ras Val-12 mutation in colorectal cancer as detected with sensitive methods. Clin Chem 1996;42:904-9.
38. Keohavong P, Zhu D, Melacrinos AC, DeMichele MAA, Weyant RJ, Luketich JD, et al. Detection of low-fraction K-ras mutations in primary lung tumors using a sensitive method, Int J Cancer 1997;74:162-70.
39. The World Health Organization histological typing of lung tumours, 2nd ed. Am J Clin Pathol 1982;77:123-36.
40. ParK JG, Oie HK, Sugarbaker PH, Henslee JG, Chen TR, Johnson BE, et al. Characteristics of cell lines established from human colorectal carcinoma. Cancer Res 1987;47:6710-8.
41. Valenzuela D, Groffen J. Four human carcinoma cell lines with novel mutations in positions 12 of c-Ki-ras oncogene. Nucleic Acids Res 1986;14:843-51.
42. Capon DJ, Seeburg PH, McGrath JP, Hayflick JS, Edma U, Levinson AD, et al. Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations. Nature 1983;304:507-13.
43. Rosell R, Monzó M, Pifarré A, Ariwa A, Sánchez JJ, Moreno I. et al. Molecular staging of non-small cell lung cancer according to K-ras genotypes. Clin Cancer Res 1996;2:1083-6.
44. Ronai Z, Yakubovskaya MS, Zhang E, Belitsky GA. K-ras mutation in sputum of patients with or without lung cancer. J Cell Biochem Suppl 1996;25:172-6.
45. Tsuchiya E, Furuta R, Wada N, Nakagawa K, Ishikawa Y. Kawabuchi B, et al. High K-ras mutation rates in goblet-cell-type adenocarcinomas of the lungs. J Cancer Res Clin Oncol 1995;121:577-81.
46. Mills NE, Fishman CL, Scholes J, Anderson SE, Rom WN, Jacobson DR. Detection of K-ras oncogene mutations in bronchoalveolar lavage fluid for lung cancer diagnosis. J Natl Cancer Inst 1995;87:1056-60.
47. Keohavong P, Zhu D, WhitesideTL, Swalsky P, Bakker A, Elder EM, et al. Detection of infrequent and multiple K-ras mutations in human tumors and tumor-adjacent tissues. Anal Biochem 1997; 247:394-403.
48. Huang MM, Arnheim N, Goodman MF. Extension of base mispairs by Tap DNA polymerase: implications for single nucleotide discrimination in PCR. Nucleic Acids Res 1992;20:4567-73.
49. Kwok S, Kellogg DE, McKinney N, Spasic D, Goda L, Levenson C, et al. Effects of primer-template mismatches on the polymerase chain reaction: human immunodeficiency virus type 1 model studies. Nucleic Acids Res 1990;18:999-1005.
50. Cline J, Braman JC, Hogrefe HH. PCR fidelity of Pfu DNA polymerase and other thermostable DNA polymerases. Nucleic Acids Res 1996;24:3546-51.